DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy

Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research

(2012) Berthold Hocher et al.   KIDNEY & BLOOD PRESSURE RESEARCH

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases

(2012) Hari Hendarto et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Renal protection in diabetes: lessons from ONTARGET®

(2010) Eberhard Ritz et al.   Cardiovascular Diabetology

Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus

(2010) Xiaoxiang Yan et al.   Cardiovascular Diabetology

Adenosine A1 receptor antagonists in clinical research and development

(2010) Berthold Hocher   KIDNEY INTERNATIONAL

eNOS Knockout Mice with Advanced Diabetic Nephropathy Have Less Benefit from Renin-Angiotensin Blockade than from Aldosterone Receptor Antagonists

(2009) Tomoki Kosugi et al.   AMERICAN JOURNAL OF PATHOLOGY

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

(2009) David J Grieve et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure

(2009) Veselin Mitrovic et al.   Circulation-Heart Failure

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

(2009) E. U. Graefe-Mody et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

(2009) T. Heise et al.   DIABETES OBESITY & METABOLISM

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

(2009) Carolyn F Deacon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Mouse Models of Diabetic Nephropathy

(2009) F. C. Brosius et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Vascular Calcification: The Killer of Patients with Chronic Kidney Disease

(2009) M. Mizobuchi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

(2008) S. Hüttner et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and −786T>C gene variants with diabetic nephropathy

(2008) Intissar Ezzidi et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

(2008) Johannes FE Mann et al.   LANCET

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy

(2008) Frank C. Brosius   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS